Abstract blue gradient split diagonally

Evidence Strategies

← All Perspectives

11/19/2026 • 9 min read

TLM 2026: What Liver Disease Researchers Need From RWE

  • Portrait of Amy Abernethy, MD, PhD

    Amy Abernethy, MD, PhD

    Co-CEO

  • Portrait of Brad Hirsch, MD

    Brad Hirsch, MD

    Co-CEO

  • Portrait of Michael W. Fried, MD, FAASLD

    Michael W. Fried, MD, FAASLD

    Co-Founder & Chief Clinical Officer

Another year, another AASLD. One might expect Michael W. Fried, MD, FAASLD, our Co-Founder and Chief Clinical Officer, to be jaded at his 38th consecutive Liver Meeting. Instead, as in years past, he found the breadth of translational and clinical research dazzling, with advances that will benefit patients with chronic liver diseases right away.

I can recount the many conversations with my patients who were just holding on, encouraging them to stay hopeful for new treatments that would alter the natural course of their diseases and, thus, the trajectory of their lives.

— Michael W. Fried, MD, FAASLD, Co-Founder & Chief Clinical Officer

Those treatments are arriving. Much as cures transformed hepatitis C, the field can now point to a therapy that can lead to functional cure of hepatitis B, the prospect of controlling, and perhaps resolving, hepatitis delta, and several management options for MASLD and PBC. For patients with diseases that never had an FDA-approved treatment or a cure, that is life changing. Many patients no longer have to watch and wait.

How the field measures liver disease and proves that treatments work is changing just as quickly. With more than 2,900 abstracts submitted and 42 late-breakers in Denver this year, the direction was clear. The field is moving from biopsy toward blood tests and scans, from lifelong viral suppression toward the possibility of cure, and from proving a drug works in a trial toward proving it works for everyone who needs it.

What stayed with us most was the tone. AASLD is a forum for advancing the leading edge of liver disease care: doing the science, conducting the clinical trials and prospective and retrospective studies, and developing approaches for clinical implementation. There is a determination to the work, without a lot of hype. We are grateful to AASLD and to the investigators, patients, and pharmaceutical and biotech companies who presented groundbreaking data and continue working to improve outcomes for patients.

Pedestal Health went to Denver as a cross-functional team of clinicians, scientists, product leaders and the research partnerships teams who work with sponsors and health systems every day. Afterward, we asked colleagues and collaborators what surprised them and what they would tell sponsors and health systems. You'll hear from:

  • K. Rajender Reddy, MD, Founders Professor of Medicine, University of Pennsylvania, on what clinicians want to know about functional cure for hepatitis B

  • Julie Crawford, MD, VP Product Strategy, on what the meeting means for our health system partners and the products we build with them

  • Dawn Drazek, MSN, CRNP, AF-AASLD, APP Clinical Lead, Hepatology, on what she sees from the clinic

  • Ashley Jaksa, MPH, Principal, Research Partnerships, on the evidence drug developers will need and the collaboration it will take to build it

Non-invasive tests were the conversation of the meeting

Deciding who should get these new treatments, and proving that they work, starts with measuring liver disease. The idea that followed us through Denver was doing that without a biopsy. Non-invasive tests, or NITs, are blood-based scores and imaging, such as vibration-controlled transient elastography (VCTE, often known by the brand name FibroScan), that estimate liver scarring. We heard about them in session rooms, in hallway conversations with people we had just met, and from investigators in our own network. The sheer consistency of that conversation surprised us. NITs are on everybody's mind, and this is good for patients.

Most patients are already followed this way. The harder question is whether, in clinical trials, a test can stand in for long-term outcomes as a reasonably likely surrogate endpoint, so a drug can be approved before longer-term clinical outcomes are known. Ashley Jaksa, our Principal, Research Partnerships, has written about that evidence standard, and why payers will ask for more than regulators do.

There is an opportunity to validate NITs like VCTE as reasonably likely surrogate endpoints for clinical trials using real-world data. Getting there depends on data that rarely sits in structured fields: elastography results usually live in clinic notes, not lab feeds. Melissa Estevez, our Head of Quantitative Sciences, has described how her team used AI-assisted abstraction to capture FibroScan results for more than 3,000 patients in a study presented at this year's meeting, and where human review still earns its cost.

For Ashley, getting there will take shared work. She heard a clear call for "pre-competitive collaboration to generate evidence to advance several liver disease areas," with companies that usually compete pooling data and effort. Forums such as the Foundation for the National Institutes of Health (FNIH) NIMBLE project, which evaluates non-invasive blood and imaging tests for fatty liver disease, have been studying this question, and the FDA has been asking it too.

Hepatitis B: a first step toward cure, and a long follow-up ahead

Hepatitis B was the largest single category among the late-breaking abstracts, 13 of 42, and it filled the hallways. Weeks before the meeting, the FDA approved bepirovirsen (Hibsago), an antisense therapy designed to achieve functional cure: the virus stays undetectable, and its surface protein disappears, for at least six months after all treatment stops. In the two phase 3 trials, about one in five patients reached that goal.

Ashley also heard a lot about what follows approval: "the need for [real-world data] to support confirmatory trials," the studies that must show a drug's benefit after an accelerated approval, in diseases like hepatitis delta and PBC. There was even discussion of synthetic data, meaning computer-generated patient records, she adds, "even though [real-world data] acceptance is still limited."

For K. Rajender (Raj) Reddy, MD, Founders Professor of Medicine at the University of Pennsylvania, the consensus across sessions and hallway conversations was that "we now have an exciting option for achieving functional cure." The question clinicians discussed most was who should get it now: all patients, or a smaller group who need it and are most likely to respond, "such as those with low HBsAg quantitative level," meaning lower amounts of the virus's surface protein in the blood. Clinicians who hadn't used bepirovirsen in a trial also wondered how well patients tolerate it and how easy it is to give.

New therapies raise new questions. Dr. Reddy's patients ask two that remain to be answered: how safe is the treatment, and if it works, how long will the cure last? He wants long-term real-world data that first tracks safety and how well the drug works, then whether the response lasts, including how many patients can stop the daily antiviral pills, called nucleos(t)ide analogues or NAs, that many take for years.

The hope is that long-term clinical trial and real-world data will demonstrate durability of response.

— K. Rajender Reddy, MD, Founders Professor of Medicine, University of Pennsylvania

Answering these questions takes years of follow-up in everyday practice, much of it carried by the health systems that treat these patients, and it means deciding now what to track.

For health system partners, thinking through the monitoring burden and other factors as new therapies are introduced, in HBV for example, will be a larger factor moving forward.

— Julie Crawford, MD, VP Product Strategy

The care gaps are measurable, and they track with who patients are

For Dawn Drazek, MSN, CRNP, our APP Clinical Lead for Hepatology, the biggest idea in Denver was "using real-world data to increase HCC surveillance and linkage to care to reduce disparities." Studies at the meeting showed why. In one multicenter cohort, only about one in four patients with cirrhosis was screened for liver cancer (HCC) every six months, as recommended, and Medicaid coverage lowered the odds (Abstract 0121). Others found similar gaps by insurance and race in transplant listing, resmetirom prescribing and hepatitis C treatment.

Julie Crawford wants to think about HCC surveillance "in terms of quality metrics," and about how to work with AASLD's new Liver Network of Excellence, a pilot launching in January 2027 to help institutions share better ways of delivering liver care.

What surprised Dawn most was a single-center study in primary biliary cholangitis (PBC) (Abstract 0119). Of 262 patients who qualified for second-line therapy, 29% received it, and none of the 19 Black patients did; for most of them, the chart showed no discussion of stepping up treatment at all. Race and insurance status, not disease severity, predicted who moved on.

Dawn also pointed to a second gap, one that opens after a prescription is written.

There is an evidence gap between a prescription being written and being filled.

— Dawn Drazek, MSN, CRNP, AF-AASLD, APP Clinical Lead, Hepatology

That gap matters to anyone who relies on real-world data, because a prescription in the chart is not proof that a patient started treatment. Each data source shows a different step: electronic health records show what was ordered, pharmacy claims show what was picked up, and patient-reported logs, which are rarely kept, show whether a patient actually took the medicine. Dawn looks forward "to working with the cross-functional team to operationalize ways to address" that challenge.

One signal, five seats: how an insight from Denver becomes evidence

Reflections only matter if they change what we do. Here is how one of them, Dawn's observation that a written prescription is not a filled one, travels through our team:

  1. The clinic notices. A clinician sees the distance between what the chart says and what the patient actually received.

  2. Clinicians define it. Hepatologists decide, before any analysis, what counts as treatment and how to confirm it, the same discipline Mike described in What Hepatitis C Taught Us About the Clinical Record.

  3. Data scientists measure it. Our quantitative scientists test how completely and accurately the variable is captured, then design analyses that account for the bias that remains.

  4. Product makes it usable. Product strategy turns those definitions and quality checks into data and measures our sponsor and health system partners can use.

  5. Partners put it to work. Our research partnerships team brings it to the sponsor or health system whose question it answers.

What we'd tell sponsors and health systems now

If you are developing a liver drug

  1. Build your longitudinal evidence generation plan early in clinical development. During development, real-world evidence can help define the target patient profile, shape trial design and put trial results in context. Closer to launch, it can show where unmet need remains and support the case for a new therapy's value. Ashley points out that planning early also supports a hybrid approach, combining trial and real-world data, so you aren't starting from scratch each time you need a new analysis or study.

  2. Design for bias from the start. "Be sure to address potential bias in real-world evidence (RWE) by working with a quantitative sciences team with expertise in RWE generation, especially in regulatory studies, with the aim to identify causal relationships," Dawn advises.

If you are a health system running liver research

  1. Start with a foundation of well-curated longitudinal clinical data. It will help you understand your population, attract studies to your institution and support patient finding for trials.

  2. Use real-world data to improve quality outcomes and health equity. That's Dawn's advice, and HCC surveillance is a natural place to start.

  3. Plan for the monitoring burden. As Julie notes, new therapies in hepatitis B and beyond will bring follow-up needs that care teams and research teams both have to absorb.

Looking toward Philadelphia

The Liver Meeting returns in Philadelphia, November 12–16, 2027. By then, some of this year's questions will have early answers: whether non-invasive tests are earning their place as endpoints, how functional cure holds up outside a trial, and whether the gaps in surveillance and treatment are starting to close. For Raj, the headline he hopes to see in hepatitis B is more treatment options, along with evidence that patients are accepting bepirovirsen, tolerating it well and responding. We intend to help generate that evidence, alongside the clinicians, investigators and sponsors who made Denver worth the trip.

If you are planning evidence for a liver program, or building research capacity in your health system, we'd welcome the conversation.

Abstract blue gradient split diagonally
Portrait of Amy Abernethy, MD, PhD

About the authors

Amy Abernethy, MD, PhD

Co-CEO

Amy is Co-CEO of Pedestal Health and cofounder of Highlander Health, with a healthcare career marked by changemaking in organizations ranging from Flatiron Health to Duke University School of Medicine and Verily. Prior to Verily, Amy served as the principal deputy commissioner of the U.S. Food and Drug Administration from 2019-2021. Her board roles span public companies such as athenahealth and CareDx to private firms including insitro and Georgiamune. In addition to her standard setting and innovation work, Amy is a hematologist/oncologist, palliative medicine physician, and author of over 500 publications and counting.

Portrait of Brad Hirsch, MD

Brad Hirsch, MD

Co-CEO

Brad is Co-CEO of Pedestal Health and cofounder of Highlander Health, and an oncologist, trialist, entrepreneur, and product leader dedicated to driving transformation at the intersection of research and care. He most recently led product at Verily, which he joined upon Verily's acquisition of SignalPath, a clinical research technology company he founded and led as CEO. In addition to past roles at Flatiron Health, Texas Oncology, US Oncology, and Duke University, Brad gives his passion and leadership to a wide range of philanthropic organizations including the National Outdoor Leadership School.

Portrait of Michael W. Fried, MD, FAASLD

Michael W. Fried, MD, FAASLD

Co-Founder & Chief Clinical Officer

Dr. Fried is Chief Clinical Officer and Co-Founder of Pedestal Health. He is also Professor of Medicine at the University of North Carolina at Chapel Hill and Past-President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried trained at the State University of New York at Syracuse and the National Institutes of Health, Bethesda, MD, which provided him with the foundation for his 30 years of experience in clinical and translational research. Dr. Fried is co-author of 200+ publications in the field of liver disease and is currently co-chair of the NIH Hepatitis B Research Network. He is co-principal investigator of the HCV-TARGET network which was awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for hepatitis C.

Talk with our team about fit-for-purpose data

See how Pedestal can support your next evidence question.

Macro photograph of translucent oil bubbles on a vibrant orange and red gradient background, evoking scientific and biological imagery.

Contact us

By submitting this form, you consent to your information used by Pedestal Health for the purpose of contacting you to better understand your potential interest in Pedestal Health and/or its services. For more information, see our privacy policy.